FIELD: biotechnology.
SUBSTANCE: disclosed is modified IgG having high binding affinity properties with neonatal Fc receptor (FcRn), which contains a constant domain of feline IgG, comprising at least one amino acid substitution as compared to a constant domain of wild-type feline IgG, a method for its preparation and use. Said substitution is in amino acid residue 428 or 434. Also disclosed are: a pharmaceutical composition and a kit for increasing the half-life of IgG in blood serum of a cat, an expression vector, an isolated host cell, the use of immunoglobulin to increase its half-life in cat’s blood serum and a fused protein.
EFFECT: invention enables prolonging the half-life of feline antibody in cat’s blood serum.
17 cl, 6 tbl, 16 dwg, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| POLYPEPTIDE VARIANTS WITH CHANGED EFFECTOR FUNCTION | 2005 |
|
RU2367667C2 |
| VARIANTS OF Fc-REGION WITH IMPROVED ABILITY TO BIND TO PROTEIN A | 2015 |
|
RU2698969C2 |
| Fc VERSIONS WITH ALTERED BINDING TO FcRn | 2021 |
|
RU2833597C2 |
| Fc-RECEPTOR BINDING MODIFIED ASYMMETRIC ANTIBODIES AND METHODS OF USE | 2014 |
|
RU2687043C2 |
| IL-8-BINDING ANTIBODIES AND USE THEREOF | 2016 |
|
RU2728430C2 |
| NOVEL ANTIBODIES | 2008 |
|
RU2490277C2 |
| METHOD FOR SELECTION AND OBTAINING OF HIGHLY SELECTIVE AND MULTISPECIFIC TARGETING GROUPS WITH SPECIFIED PROPERTIES, INCLUDING AT LEAST TWO DIFFERENT BINDING GROUPS, AND THEIR APPLICATIONS | 2013 |
|
RU2639287C2 |
| ANTIBODIES AGAINST HUMAN CD19 WITH HIGH AFFINITY | 2016 |
|
RU2761077C1 |
| ANTIBODIES AGAINST A2 TENASTIN-C AND METHODS FOR USE THEREOF | 2011 |
|
RU2584597C2 |
| IN VITRO PREDICTION OF ANTIBODY HALF-LIFE IN VIVO | 2015 |
|
RU2688349C2 |
